Efficacy,safety and prognosis of trastuzumab combined with fluvestrant in the treatment of advanced breast cancer
Objective To investigate the efficacy,safety and prognosis of trastuzumab combined with fluvestrant in the treatment of advanced breast cancer.Methods A retrospective analysis was performed on 60 postmenopausal women with HER2-positive HR+metastatic breast cancer treated in our hospital from June 2016 to April 2017.All patients had received conventional chemotherapy.Thirty patients who were treated with trastuzumab and fluvistrane were selected as the study group.The other 30 patients who were treated with trastuzumab were selected as the control group.After 6 months for treating,the two groups were given tamoxifen and fluvistrane continuous treating respectively.The differences of the treatment effect,prognosis and survival,adverse reactions,AIB1,ATF3 and quality of life between the two groups were compared.The two groups were followed up for 3 years,and the postoperative survival was compared.Results ①Through the follow-up of all patients,the follow-up rate was 97％(58/60),and the OS and PFS of the observation group were significantly higher than those of the control group(P＜0.05);②There were no significant differences in abnormal liver function,low fever,fatigue and so on between the two groups(P＞0.05);③ After treatment,the levels of AIB1 and ATF3 in the two groups were significantly decreased,and the levels of AIB1 and ATF3 in the observation group were significantly lower than those in the control group(P＜0.05);④After treatment,the physiological function,physiological function,physical pain,general health,energy,social function,emotional function,mental health,and total scores of the patients in the two groups significantly increased,and those in observation group were significantly higher than those in the control group(P＜0.05);⑤After treatment,there were significant differences in the objective effective rate and disease control rate between the two groups,which in the study group were higher than those in the control group(P＜0.05).Conclusion Trastuzumab combined with fulvestrant therapy in patients with advancend breast cancer can improve the levels of AIB1 and ATF3,and improve the clinical treatment effect and quality of life of patients.
Breast neoplasmsTrastuzumabFulvestrantQuality of life
万方数据
维普
